Kuan-Chieh Huang

Mitigating ipatasertib‐induced glucose increase through dose and meal timing modifications

R. Sane, P. Agarwal, Dhruvitkumar S. Sutaria, 2022, Clinical and translational science.

Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF V600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

P. Ascierto, H. Gogas, P. Rutkowski, 2020, The Lancet.

Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous Non-Small-Cell Lung Cancer (IMpower131): Results From a Randomized Phase III Trial.

M. Socinski, F. Cappuzzo, V. Graupner, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Using Deep Neural Networks for Predicting Age and Sex in Healthy Adult Chest Radiographs

Chung-Yi Yang, Hung-Chieh Chen, Yi-Ju Pan, 2021, Journal of clinical medicine.

OA14.02 IMpower131: Final OS Results of Carboplatin + Nab-Paclitaxel ± Atezolizumab in Advanced Squamous NSCLC

M. Socinski, R. Soo, M. Mccleland, 2019, Journal of Thoracic Oncology.

A Robust, Fully Automatic Detection Method and Calculation Technique of Midline Shift in Intracranial Hemorrhage and Its Clinical Application

Pin-Yuan Chen, Jiun-Lin Yan, Meng-Chi Hsieh, 2022, Diagnostics.

Patient-reported outcomes (PROs) from the phase III IMspire150 trial of atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in patients (pts) with BRAFV600+melanoma.

P. Ascierto, H. Gogas, P. Rutkowski, 2020, Journal of Clinical Oncology.

A phase Ib, open-label study evaluating the safety and efficacy of ipatasertib + rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC).

J. Carles, F. D. De Braud, D. Geynisman, 2022, Journal of Clinical Oncology.